SZSE:300347

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Hangzhou Tigermed ConsultingLtd

Executive Summary

Hangzhou Tigermed Consulting Co., Ltd. operates as a contract research organization in China and internationally. More Details


Snowflake Analysis

Flawless balance sheet with proven track record.


Similar Companies

Share Price & News

How has Hangzhou Tigermed ConsultingLtd's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 300347 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: 300347's weekly volatility (8%) has been stable over the past year.


Market Performance


7 Day Return

-23.5%

300347

-16.4%

CN Life Sciences

-6.4%

CN Market


1 Year Return

83.8%

300347

88.3%

CN Life Sciences

26.5%

CN Market

Return vs Industry: 300347 underperformed the CN Life Sciences industry which returned 88.3% over the past year.

Return vs Market: 300347 exceeded the CN Market which returned 26.5% over the past year.


Shareholder returns

300347IndustryMarket
7 Day-23.5%-16.4%-6.4%
30 Day-16.0%-11.7%-1.8%
90 Day23.3%31.6%2.8%
1 Year84.4%83.8%88.9%88.3%28.5%26.5%
3 Year447.1%440.7%264.0%259.8%27.9%21.6%
5 Year651.1%637.3%257.2%251.2%44.1%34.1%

Long-Term Price Volatility Vs. Market

How volatile is Hangzhou Tigermed ConsultingLtd's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Hangzhou Tigermed ConsultingLtd undervalued compared to its fair value and its price relative to the market?

66x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 300347 (CN¥140.58) is trading above our estimate of fair value (CN¥89.55)

Significantly Below Fair Value: 300347 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 300347 is good value based on its PE Ratio (66x) compared to the CN Life Sciences industry average (92.7x).

PE vs Market: 300347 is poor value based on its PE Ratio (66x) compared to the CN market (34.1x).


Price to Earnings Growth Ratio

PEG Ratio: 300347 is poor value based on its PEG Ratio (6.4x)


Price to Book Ratio

PB vs Industry: 300347 is overvalued based on its PB Ratio (7.7x) compared to the CN Life Sciences industry average (7x).


Next Steps

Future Growth

How is Hangzhou Tigermed ConsultingLtd forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?

10.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 300347's forecast earnings growth (10.3% per year) is above the savings rate (3.3%).

Earnings vs Market: 300347's earnings (10.3% per year) are forecast to grow slower than the CN market (24.8% per year).

High Growth Earnings: 300347's earnings are forecast to grow, but not significantly.

Revenue vs Market: 300347's revenue (22.6% per year) is forecast to grow faster than the CN market (18.3% per year).

High Growth Revenue: 300347's revenue (22.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 300347's Return on Equity is forecast to be low in 3 years time (12.5%).


Next Steps

Past Performance

How has Hangzhou Tigermed ConsultingLtd performed over the past 5 years?

49.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 300347 has a high level of non-cash earnings.

Growing Profit Margin: 300347's current net profit margins (53.1%) are higher than last year (25%).


Past Earnings Growth Analysis

Earnings Trend: 300347's earnings have grown significantly by 49.8% per year over the past 5 years.

Accelerating Growth: 300347's earnings growth over the past year (138.5%) exceeds its 5-year average (49.8% per year).

Earnings vs Industry: 300347 earnings growth over the past year (138.5%) exceeded the Life Sciences industry 34.4%.


Return on Equity

High ROE: 300347's Return on Equity (10.3%) is considered low.


Next Steps

Financial Health

How is Hangzhou Tigermed ConsultingLtd's financial position?


Financial Position Analysis

Short Term Liabilities: 300347's short term assets (CN¥12.5B) exceed its short term liabilities (CN¥899.5M).

Long Term Liabilities: 300347's short term assets (CN¥12.5B) exceed its long term liabilities (CN¥403.8M).


Debt to Equity History and Analysis

Debt Level: 300347's debt to equity ratio (0.1%) is considered satisfactory.

Reducing Debt: 300347's debt to equity ratio has reduced from 17.6% to 0.1% over the past 5 years.

Debt Coverage: 300347's debt is well covered by operating cash flow (2976.1%).

Interest Coverage: 300347 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Hangzhou Tigermed ConsultingLtd current dividend yield, its reliability and sustainability?

0.20%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 300347's dividend (0.2%) isn’t notable compared to the bottom 25% of dividend payers in the CN market (0.4%).

High Dividend: 300347's dividend (0.2%) is low compared to the top 25% of dividend payers in the CN market (1.8%).


Stability and Growth of Payments

Stable Dividend: 300347 is not paying a notable dividend for the CN market, therefore no need to check if payments are stable.

Growing Dividend: 300347 is not paying a notable dividend for the CN market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: 300347 is not paying a notable dividend for the CN market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 300347's dividend in 3 years as they are not forecast to pay a notable one for the CN market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average management tenure


CEO

Xiaochun Cao (51 yo)

1.83yrs

Tenure

CN¥784,100

Compensation

Dr. Xiaochun Cao, M.D., serves as Consultant at TigerYeah Capital. She co-founded Hangzhou Tigermed Consulting Co., Ltd. and serves as President since 2019 also its General Manager since April 25, 2019. Dr...


Leadership Team

NamePositionTenureCompensationOwnership
Xiao Ping Ye
Founder & Chairman2.08yrsCN¥818.20k20.31%
CN¥ 24.6b
Xiaochun Cao
Co-Founder1.83yrsCN¥784.10k6.55%
CN¥ 7.9b
Gao Jun
Senior VP of Investment4.17yrsCN¥1.67mno data
Zhuan Yin
Deputy GM & Non-Independent Director6.92yrsCN¥753.40k1.18%
CN¥ 1.4b
Guoyun Yu
Head of Accounting Departmentno datano datano data
Qing Li
Vice President of Human Resources & Field Service3.17yrsno datano data
Xiao Li Shi
VP, Head of Data Resources Department & Member of Supervisory Board3.67yrsno data1.42%
CN¥ 1.7b
Binghua Su
Chief Biostatistician4yrsno datano data
Helen Yin
Senior Vice President of Biometricsno datano datano data
Liu Minzhi
Partnerno datano datano data
Song Li
Senior VP of CMC & Biological Analysis Business Line4yrsno datano data
Jia Liu
VP & Head of International Business4.25yrsno datano data

4.0yrs

Average Tenure

53yo

Average Age

Experienced Management: 300347's management team is considered experienced (4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Xiao Ping Ye
Founder & Chairman2.08yrsCN¥818.20k20.31%
CN¥ 24.6b
Xiaochun Cao
Co-Founder1.83yrsCN¥784.10k6.55%
CN¥ 7.9b
Zhuan Yin
Deputy GM & Non-Independent Director6.92yrsCN¥753.40k1.18%
CN¥ 1.4b
Xiao Li Shi
VP, Head of Data Resources Department & Member of Supervisory Board3.67yrsno data1.42%
CN¥ 1.7b
Bing Hui Zhang
Non-Employee Supervisory0.83yrCN¥72.00kno data
Bo Yang
Independent Director0.83yrno datano data
Zhimin Chen
Non-Employee Supervisor0.83yrCN¥96.00kno data
Bijun Zheng
Independent Director3.5yrsCN¥96.00kno data
Qiyu Liao
Independent Director0.83yrno datano data

2.1yrs

Average Tenure

55yo

Average Age

Experienced Board: 300347's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.4%.


Top Shareholders

Company Information

Hangzhou Tigermed Consulting Co.,Ltd's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Hangzhou Tigermed Consulting Co.,Ltd
  • Ticker: 300347
  • Exchange: SZSE
  • Founded: 2004
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CN¥120.942b
  • Shares outstanding: 872.48m
  • Website: https://tigermedgrp.com

Number of Employees


Location

  • Hangzhou Tigermed Consulting Co.,Ltd
  • No. 19 Jugong Road
  • Room 2001-2010, 20th Floor
  • Hangzhou
  • Zhejiang Province
  • 310053
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
300347SZSE (Shenzhen Stock Exchange)YesDomestic SharesCNCNYAug 2012
300347XSEC (Shenzhen Stock Exchange - Shenzhen-Hong Kong Stock Connect)YesDomestic SharesCNCNYAug 2012
3347SHSC (Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect)Foreign Shares-Foreign ListedHKHKDAug 2020
3347SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect)Foreign Shares-Foreign ListedHKHKDAug 2020
3347SEHK (The Stock Exchange of Hong Kong Ltd.)Foreign Shares-Foreign ListedHKHKDAug 2020

Biography

Hangzhou Tigermed Consulting Co., Ltd. operates as a contract research organization in China and internationally. The company offers regulatory submission and approval, medical translation, and good manufa...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/02/28 09:05
End of Day Share Price2021/02/26 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.